Skip to main content

Table 3 Summary of expected absorbed dose (based on the assumption of invariable uptake after the first cycle) compared to the delivered absorbed dose (n = 6) for the tumour and kidney

From: Impact of cyclic changes in pharmacokinetics and absorbed dose in pediatric neuroblastoma patients receiving [177Lu]Lu-DOTATATE

 

Absorbed dose per cycle (Gy)

Expected assuming fixed biokinetics, ADE

Delivered, ADD

Ratio (ADD/ADE)

p value

Tumour

    

 Cycle 1

15.6 (8.10–26.4)

15.6 (8.1–26.4)

1

 Cycle 2

22.6 (10.6–35.6)

11.4 (9.7–28.8)

0.76 (0.42–1.00)

p > 0.05

 Cycle 3

24.2 (10.9–34.8)

11.3 (2.7–32.9)

0.39 (0.25–0.94)

p > 0.05

 Cycle 4

25.8 (11.3–40.8)

4.3 (0.7–20.1)

0.16 (0.02–0.92)

0.013

Kidney

    

 Cycle 1

1.40 (0.66–2.60)

1.40 (0.66–2.60)

1

 Cycle 2

1.91 (0.89–3.34)

1.39 (0.66–3.20)

0.74 (0.69–1.02)

p > 0.05

 Cycle 3

1.95 (0.87–4.26)

1.71 (1.28–3.03)

1.01 (0.35–2.03)

p > 0.05

 Cycle 4

2.06 (1.02–3.86)

2.40 (1.79–4.02)

1.08 (0.84–1.76)

p > 0.05

  1. Data are presented as median (range)